Cell line · CVCL_8795
OCI-Ly10
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma activated B-cell type. 36 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Cite this record
ConductScience Library. OCI-Ly10. Cell lines, record CVCL_8795. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_8795
On this page
Cell line
As Cellosaurus gives it.
- Name
- OCI-Ly10
- Accession
- CVCL_8795
- RRID
- RRID:CVCL_8795
- Synonyms
- OCI-LY10, OCI-LY-10, OCI-Ly 10, OCILY-10, OCI Ly10, OCILY10, OCILy10, Ly10, LY10
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 66Y
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma activated B-cell type (NCIt C36081); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Lymph node (in situ)
- Entry created
- 2012-06-06
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers36
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. | Blood Cancer J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sodium-myoinositol cotransporter-1 downstream of m6A methyltransferase WTAP exerts a potential carcinogenicity in diffuse large B-cell lymphoma progression. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Xenopus IgX informs engineering strategies of IgM and IgG hexamers. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B4 suppresses lymphoma progression by inhibiting fibroblast growth factor binding protein 1 through intrinsic apoptosis. | Front Pharmacol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Plasmodium falciparum has evolved multiple mechanisms to hijack human immunoglobulin M. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 36
See all 36 papersRelatives0
None in this release.
Cell banks0
None in this release.
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8795
GET https://conductscience.org/api/cell-lines/v1/CVCL_8795/papers?page=2